Surgical procedures and non-surgical devices for the management of non-apnoeic snoring: a systematic review of clinical effects and associated treatment costs

C Main,1* Z Liu,1 K Welch,2 G Weiner,3 SQ Jones4 and K Stein1

1Peninsula Technology Assessment Group (PenTAG), University of Exeter, UK
2Southampton Health Technology Assessment Centre, Southampton, UK
3Royal Devon and Exeter Hospital Trust, Exeter, UK
4Cardiff University Dental Hospital, Cardiff, UK

*Corresponding author

Executive summary

Health Technology Assessment 2009; Vol. 13: No. 3
DOI: 10.3310/hta13030
Executive summary

Background

Snoring is the hallmark symptom of a spectrum of sleep-related breathing disorders (sleep-disordered breathing, SDB). The pathophysiological cause of SDB is sleep-induced airway obstruction. Minimal airway obstruction causes non-apnoeic, or simple, snoring. At the other extreme, complete airway obstruction causes obstructive sleep apnoea syndrome (OSAS).

Snoring is very common in the general population, with around 35–45% of men and 15–28% of women reporting habitual snoring. However, although the clinical significance of non-apnoeic snoring remains equivocal, its psychosocial impact is easily recognised. Loud intrusive snoring affects bed partners, family and even neighbours. Noise pollution and its resulting social disability and relationship disharmony is an important reason why an individual will seek medical advice.

There are a number of surgical procedures and non-surgical devices for the management of non-apnoeic snoring, and the most appropriate treatment option depends on the level of airway obstruction, the intensity of the snoring sound, and the characteristics of the individual patient. Prior to being considered for surgery or use of a CPAP machine all patients must have a diagnosis of sleep apnoea excluded by undergoing either overnight polysomnography (PSG) or modified PSG. Additionally, the site of airway obstruction will be examined to ensure adequate patient selection for each procedure.

Objectives

To review the evidence on the clinical effects and associated treatment costs of surgical procedures and non-surgical devices for the management of non-apnoeic snoring.

Methods

A systematic review was undertaken. MEDLINE, EMBASE, CINAHL, Cochrane Controlled Trials Register (CCTR) and NHS EED were searched for relevant studies of clinical effects and treatment costs published between 1980 and 2007.

Randomised controlled trials (RCTs), cross-over trials, controlled clinical trials (CCTs), and pre–post studies that reported an objectively assessed outcome measure in patients eligible for surgical procedures or the use of non-surgical devices for non-apnoeic snoring were included. Non-surgical devices included were: continuous positive airway pressure (CPAP); mandibular advancement splints (MAS); and tongue-retaining devices (TRD). Surgical procedures included were: surgery for coincidental nasal obstruction; uvulopalatopharyngoplasty (UP3) with or without tonsillectomy; laser-assisted uvulopalatoplasty (LAUP); uvulopalatal elevation palatoplasty (UEP); uvulectomy alone; palatal stiffening techniques (injection snoreplasty, cautery-assisted palatal stiffening, diathermy assisted uvulopalatoplasty, Pillar implants); radiofrequency ablation (RFA) of the soft palate or tongue base; and tongue base suspension procedures. Studies of mandibular/maxillary advancement procedures were excluded. All interventions were compared with each other, placebo, lifestyle modification techniques or no intervention.

Outcome measures of interest were objective snoring sound indices; patient- and/or bed partner-reported snoring severity; PSG parameter measurements; and cephalometric radiographs or magnetic imaging scans of palatal width or length. Treatment complications and the need for repeat procedures were also assessed.

Review methods and data synthesis

Studies were screened for inclusion, data extracted, and quality assessed independently by two reviewers. Results were broadly grouped according to the intervention and comparator, where applicable, and study design. Results were combined using a narrative synthesis with relevant quantitative results tabulated.
Treatment costs

The indicative costs of the surgical procedures and non-surgical devices included initial treatment costs, as well as the ongoing costs of care associated with the interventions. The cost of diagnostic tests, i.e. PSG or modified PSG to exclude a diagnosis of sleep apnoea, were not included in the treatment costs. No studies were identified by the searches that had assessed the costs associated with any of the included interventions. Costs were therefore estimated based on the NHS reference costs (2006), data from device manufacturers, and clinical opinion. It was not possible to estimate a cost associated with RFA of the soft palate or tongue base, as the cost of the somnoplasty generator and electrodes was considered to be ‘commercial in confidence’ on approach to the device manufacturers, and was not otherwise available in the public domain.

The limited analysis of rough cost estimates for the other surgical procedures assumed that each procedure would entail an initial consultation with an ear, nose and throat (ENT) surgeon, specific inpatient or day-case procedure time, device costs (where relevant) and a follow-up consultation. For UP3 it was assumed that the procedure would entail an inpatient stay of 1 day, and for LAUP (which can be conducted as a 1-, 2- or 3-stage sequential procedure) that each additional procedure was associated with one additional follow-up visit. For CPAP, as there are numerous machines and face masks available, the mean cost of the devices available was used and a device life of 7 years with an annual replacement cost of the face mask assumed. Additionally, it was assumed that patients would undergo an initial consultation and a session with a specialist nurse for device titration. For costs associated with MAS, it was assumed that the dentist provided a Thornton Adjustable Positioning® (TAP) device, and that the device life was 2 years. For each subsequent year of MAS use, it was assumed that an annual check-up would be necessary. Costs of both the CPAP machine and MAS were expressed as equivalent annual costs using the discount rate of 3.5%.

Results

A total of 1903 titles and abstracts were screened for inclusion, with 27 studies reported in 30 publications meeting the inclusion criteria. The identified studies assessed a broad range of interventions. These could broadly be grouped into studies assessing UP3 versus LAUP (n = 2), UP3 alone (n = 7), LAUP alone (n = 3), palatal stiffening techniques (Pillar implants and injection snoreplasty) (n = 5), RFA of the soft palate or tongue base (n = 7), CPAP (n = 1) and MAS (n = 2). No studies were identified that assessed surgery to improve coincidental nasal obstruction alone, uvulectomy alone, DAUP or tongue base suspension procedures.

Studies were generally of a low methodological quality with small sample sizes. A total of 1191 patients had been included. The evidence consisted of three randomised controlled trials (11%), two controlled clinical trials (7.5%), and 22 pre–post studies (81.5%). In the five controlled studies, very few between-group comparisons were reported, with data analysed as a change in the pre- and post-treatment mean for each group separately. Lack of any between-group comparisons and heterogeneity between the studies in the interventions assessed, treatment protocols and outcome measures means that few between-study comparisons could be drawn.

Uvulopalatopharyngoplasty versus laser-assisted uvulopalatoplasty

On subjective measures of snoring, evidence from one RCT (n = 47) and one CCT (n = 60) on the effects of UP3 versus LAUP is equivocal. Where there were significant differences between the procedures, these favoured treatment with UP3 (n = 45), but on other measures there were no significant differences. This finding is consistent with evidence that both procedures were effective at reducing the number of snores per hour postoperatively (n = 23), but there were no significant differences between the procedures. Additionally, both UP3 and LAUP were effective at reducing snoring loudness (n = 23), but this reduction is modest (3.8 dB). Adverse events between the two procedures were comparable (n = 47), except for levels of postoperative pain, which were significantly higher in the UP3 group (n = 18).

Uvulopalatopharyngoplasty alone

Evidence on the effects of UP3 from seven pre–post studies (n = 538) shows that UP3 is effective in reducing a number of subjectively reported snoring indices. Overall results from four studies that assessed objective measures of snoring sound parameters were equivocal (n = 184). Postoperative pain, where reported, was moderate, but all morbidity associated with the procedure was minor.
Laser-assisted uvulopalatoplasty alone

Limited evidence from three pre–post studies \((n = 58)\) on LAUP supports the fact that subjectively assessed snoring status or scores were improved after the procedure. None of the studies on LAUP had assessed objectively evaluated snoring sounds. Levels of postoperative pain were mild to moderate, and all adverse events were minor.

Radiofrequency ablation of the soft palate

Results from six pre–post studies \((n = 142)\) show that RFA is associated with a postoperative reduction in partner-assessed snoring intensity. Snoring intensity was reduced from a mean pre-treatment range of 6.5–8.4 to a mean post-treatment range of 2.75–5.2 as assessed on a 10-point visual analogue scale. Evidence for effects of RFA on an objective reduction in snoring sound levels from three studies \((n = 50)\) is mixed. Levels of postoperative pain, swallowing, speech, taste and pharyngeal irritation were rated as low to moderate. Rates of mucosal blanchings and erosions ranged from 15% to 40%.

Pillar implants

Four pre–post studies \((n = 107)\) indicated that Pillar implants are effective at reducing partner-rated snoring intensity. Snoring intensity was reduced from a mean pre-treatment range of 7.1–7.9 to a mean post-treatment range of 4.7–4.8. Evidence on the effects of Pillar implants on objective snoring indices from one study \((n = 40)\) showed no significant differences between pre- and post-treatment levels. Postoperative pain levels were either mild or moderate, whilst swallowing and speech difficulties were rated as mild. The rate of implant extrusions ranged from 0% to 11%.

Continuous positive airway pressure

The only available evidence on the effects of CPAP for the treatment of non-apnoeic snoring came indirectly from a two-group parallel pre–post study with nine patients in the treatment group. Results showed that use of CPAP at 5.3 cmH\(_2\)O (range: 3–8 cmH\(_2\)O) reduced the number of snores per hour from a mean of 387 (SD: 150) to a mean of 15.1 (SD: 2.5). No subjective snoring scores were evaluated.

Mandibular advancement splints

Evidence on the effects of MAS from three studies \((n = 72)\) was limited to objective snoring sound outcomes. This suggests that MAS significantly improve a number of objective snoring sound parameters. Data from one study \((n = 35)\) reporting adverse effects showed that the percentage of minor side effects was relatively high, particularly for muscular and temperomandibular joint discomfort in the initial days of MAS use. Minor side effects remained relatively common but these all decreased within the first month of use.

Summary of costs

Limited analysis indicates that the cost for UP3 is approximately £1250, assuming that patients have a 1-day hospital stay, but rises to approximately £1550 if patients require an additional day of hospitalisation. For LAUP, the cost associated with one procedure is approximately £790 but rises to £1450 for a two-stage sequential procedure and £2070 for a three-stage procedure. The treatment costs associated with the use of Pillar implants range from £1110 to £1160 (depending on the manufacturer’s discount). When use of either a CPAP machine or MAS is considered, the approximate annual treatment costs associated with the use of each device are £220 and £130 respectively.

Conclusions

There appear to be no consistent significant differences in effects between UP3 compared with LAUP on snoring levels. UP3, LAUP, RFA of the soft palate and Pillar implants are all associated with a significant reduction in patient- or bed partner-reported snoring levels. However, the rate of relapse on subjectively assessed outcomes is variable and ranges from approximately 6% to 24%, depending on the procedure and the length of postoperative follow-up. There is no strong evidence that subjectively assessed snoring outcomes are associated with objective reductions in snoring sound levels.

Very limited evidence on CPAP and MAS shows that both devices are associated with a significant reduction in objective snoring sound parameters, which if realised may translate into a significant reduction in bed partner-assessed snoring intensity.
In terms of UP3, LAUP and Pillar implants, there is no procedure that is clearly the least-cost option based on the crude and limited analysis conducted. For use of CPAP or MAS, use of MAS appears cheaper than use of a CPAP machine. However, there is considerable variation in the cost of both devices, and use of more expensive MAS and less expensive CPAP machines may reverse the cost relationship.

**Publication**

The Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA Programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender.

Second, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.

Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned and funded by the HTA Programme on behalf of NICE as project number 07/17/01. The protocol was agreed in August 2007. The assessment report began editorial review in January 2008 and was accepted for publication in June 2008. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health.

Editor-in-Chief: Professor Tom Walley
Series Editors: Dr Aileen Clarke, Dr Peter Davidson, Dr Chris Hyde, Dr John Powell, Dr Rob Riemsmma and Professor Ken Stein